Any current/future capex/capital investment/strategic investment?

The company has completed major CAPEX projects, including the commissioning of a Brownfield hydrogenation plant at Vadodara (commissioned July 2020) and a greenfield project in Mahad, which is in advanced commissioning and expected to contribute from the second half of FY 2024-2025. The hydrogenation facility is multi-product, targeting 6-7 products with ~700 tons annual capacity, expected to reach 70-80% utilization within 4-5 quarters. Mahad plant is initially a single product plant with ~250 metric tons capacity, aiming for full stabilization 2-3 quarters after going live. Incremental depre

Future growth expectations in sales/revenue/volumes?

Expected peak revenue of around ₹1200 crore post full capacity utilization of new plants (next few quarters). New hydrogenation facility (multi-product) aimed at 700 tons annual capacity, expected to reach 70-80% utilization within 4-5 quarters. Mahad single product plant phased for 250 metric tons with a stabilization timeline of 2-3 quarters post-launch. Anticipated top line growth from new capacities starting contribution from Q3 FY 2024-25 (Baroda) and second half FY 2024-25 (Mahad). Continuous product approvals and phased growth expected; timeline for products moving from marginal

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects to achieve a top line of approximately Rs. 1200 crores after the new plants reach full capacity over the next 2-3 quarters. EBITDA guidance for the current year stands at 10% to 12%, with confidence in meeting or exceeding this range over the next two quarters. There is optimism for both volume growth and better realizations across divisions, potentially driving top line growth. The company aims for steady-state growth with ongoing new product launches and capacity expansions contributing to profitability. Long-term EBITDA margin guidance remains at 14% to 17%, expe

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders in specific numeric terms. However, it indicates healthy demand across divisions and positive outlook for the next 2-3 quarters. The fragrance division continues to acquire new customers and sees growth from new business opportunities. Increased allocations have been received from key customers for the second half of FY 2024-25, signaling strong order momentum. New plants (hydrogenation plant at Vadodara and Greenfield plant at Mahad) are expected to contribute to the top line from the secon

Oriental Aromat.Q1 FY25Chemicals & Petrochemicals

Oriental Aromat. Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹532P/E: 337.6Market Cap: ₹1.8K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Expected peak revenue of around ₹1200 crore post full capacity utilization of new plants (next few quarters).
New hydrogenation facility (multi-product) aimed at 700 tons annual capacity, expected to reach 70-80% utilization within 4-5 quarters.
Mahad single product plant phased for 250 metric tons with a stabilization timeline of 2-3 quarters post-launch.
Anticipated top line growth from new capacities starting contribution from Q3 FY 2024-25 (Baroda) and second half FY 2024-25 (Mahad).
Continuous product approvals and phased growth expected; timeline for products moving from marginal to major supplier status is 2-3.5 years.
India and "China Plus One" strategy considered positive drivers for growth.
Management cautiously optimistic about volume and revenue growth but refrains from exact percentage guidance currently due to approvals and pricing finalization.

Margin guidance

Category 3

The company expects to achieve a top line of approximately Rs. 1200 crores after the new plants reach full capacity over the next 2-3 quarters.
EBITDA guidance for the current year stands at 10% to 12%, with confidence in meeting or exceeding this range over the next two quarters.
There is optimism for both volume growth and better realizations across divisions, potentially driving top line growth.
The company aims for steady-state growth with ongoing new product launches and capacity expansions contributing to profitability.
Long-term EBITDA margin guidance remains at 14% to 17%, expected to normalize as new CAPEX-related efficiencies come into play.
Peak debt is projected around Rs. 280 crores at the group level, managed conservatively without compromising financial prudence.
Cautious optimism is expressed around India’s growing market and China Plus One strategy enhancing growth opportunities.

See what Oriental Aromat. management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

- The company has already taken term loans for ongoing projects: Downfield project has only Rs. 20 crore outstanding, and Mahad project’s highest debt would be Rs. 70 crore. - Peak debt for the current financial year is expected at Rs. 200 crore for the parent company and Rs. 80 crore for the subsidiary, totaling Rs. 280 crore at the group level. - Around Rs. 85 crore of the debt is long-term (term loans), and the rest is working capital debt, supported by inventories. - The management states they are conservative with debt and have no indication of raising additional equity or significantly increasing debt beyond planned levels. - Future CAPEX beyond current projects may happen but has not been detailed; earlier planned CAPEX has been implemented. - They aim to further reduce debt over time and maintain healthy debt ratios. There are no announcements of new fundraising through debt or equity at present.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders in specific numeric terms.
However, it indicates healthy demand across divisions and positive outlook for the next 2-3 quarters.
The fragrance division continues to acquire new customers and sees growth from new business opportunities.
Increased allocations have been received from key customers for the second half of FY 2024-25, signaling strong order momentum.
New plants (hydrogenation plant at Vadodara and Greenfield plant at Mahad) are expected to contribute to the top line from the second half of FY 2024-25, implying an improving order pipeline.
The company is in a phase of product approval and volume ramp-up, indicating ongoing and future product orders are being finalized and will contribute progressively.

See what Oriental Aromat. management said on order book — free account, 30 seconds.

Capex plans

Yes

The company has completed major CAPEX projects, including the commissioning of a Brownfield hydrogenation plant at Vadodara (commissioned July 2020) and a greenfield project in Mahad, which is in advanced commissioning and expected to contribute from the second half of FY 2024-2025.
The hydrogenation facility is multi-product, targeting 6-7 products with ~700 tons annual capacity, expected to reach 70-80% utilization within 4-5 quarters.
Mahad plant is initially a single product plant with ~250 metric tons capacity, aiming for full stabilization 2-3 quarters after going live.
Incremental depreciation from new facilities expected to be Rs. 8-10 crores annually.
Peak group-level debt expected at Rs. 280 crores for ongoing expansions.
Future CAPEX beyond these projects is possible but currently unspecified, with a cautious and conservative approach to funding and debt management.
The company is optimistic about capturing growth opportunities driven by new capacities and "China Plus One" customer shifts.

Track Oriental Aromat. — get its next earnings analysis in your feed

How does Oriental Aromat. rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisOriental Aromat.

Rev 3Mar 3

See where Oriental Aromat. sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Oriental Aromat. rank in Chemicals & Petrochemicals?

Compare Oriental Aromat. against every Chemicals & Petrochemicals company (Q1 FY25) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Oriental Aromat.'s management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Oriental Aromat. Q1 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Oriental Aromat. rank in Chemicals & Petrochemicals?

Continue your research

What Oriental Aromat.'s management said in earlier quarters

Others in Chemicals & Petrochemicals this season